The DOI matches its Crossref record; 202 of the 202 references it cites were found in a registry or an index.
Osteoporosis Due to Cancer Treatment: Pathogenesis and Management
Abstract
Many therapeutic regimens in cancer treatment carry the risk of causing or favoring the development of osteoporosis. Therapies in which hypogonadism may occur are most relevant in this respect. Prompt hormone replacement therapy is indicated in these patients. In patients in whom this is undesirable because of a hormone-dependent tumor, the risk of osteoporosis should be assessed by means of osteodensitometry, and prophylactic or therapeutic measures should be instituted if necessary. Early intervention improves outcome because osteoporosis therapy is most effective in preventing deterioration of bone mass. There remains much uncertainty in assessing the risk of combination chemotherapy with regard to the development of osteoporosis. Negative effects on the skeleton have, however, been demonstrated for individual drugs, such as methotrexate and ifosfamide. Negative effects of the tumor itself on bone metabolism may aggravate the degree of osteoporosis. Detailed data and long-term experience to assess the risk are urgently needed in this area and constitute an important research topic for the coming years and decades. This review discusses the most prevalent mechanisms of osteoporosis caused by cancer treatment and outlines therapeutic strategies for the prevention and treatment of therapy-induced bone loss.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Wimalawansa, S. J. (1995) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)80102-8 · Cited by 152
RetractedProfessor Kanis, J. A., Melton, L. J., Christiansen, C., Johnston, C. C., & Khaltaev, N. (1994) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650090802 · Cited by 3,849
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Marshall, D., Johnell, O., & Wedel, H. (1996) · BMJ · doi:10.1136/bmj.312.7041.1254 · Cited by 3,709
Risk Factors for Hip Fracture in White Women
Cummings, S. R., Nevitt, M. C., Browner, W. S., Stone, K., Fox, K. M., Ensrud, K. E., Cauley, J., Black, D., & Vogt, T. M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199503233321202 · Cited by 3,595
Vitamin D3and Calcium to Prevent Hip Fractures in Elderly Women
Chapuy, M. C., Arlot, M. E., Duboeuf, F., Brun, J., Crouzet, B., Arnaud, S., Delmas, P. D., & Meunier, P. J. (1992) · New England Journal of Medicine · doi:10.1056/nejm199212033272305 · Cited by 2,950
Consensus development conference: Diagnosis, prophylaxis, and treatment of osteoporosis
(1993) · The American Journal of Medicine · doi:10.1016/0002-9343(93)90218-e · Cited by 2,874
Estrogen Resistance Caused by a Mutation in the Estrogen-Receptor Gene in a Man
Smith, E. P., Boyd, J., Frank, G. R., Takahashi, H., Cohen, R. M., Specker, B., Williams, T. C., Lubahn, D. B., & Korach, K. S. (1994) · New England Journal of Medicine · doi:10.1056/nejm199410203311604 · Cited by 2,471
Liberman, U. A., Weiss, S. R., Bröll, J., Minne, H. W., Quan, H., Bell, N. H., Rodriguez-Portales, J., Downs, R. W., Dequeker, J., Favus, M., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511303332201 · Cited by 2,288
Dawson-Hughes, B., Harris, S. S., Krall, E. A., & Dallal, G. E. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709043371003 · Cited by 2,277
Delmas, P. D., Bjarnason, N. H., Mitlak, B. H., Ravoux, A.-C., Shah, A. S., Huster, W. J., Draper, M., & Christiansen, C. (1997) · New England Journal of Medicine · doi:10.1056/nejm199712043372301 · Cited by 1,637
Alendronate for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis
Saag, K. G., Emkey, R., Schnitzer, T. J., Brown, J. P., Hawkins, F., Goemaere, S., Thamsborg, G., Liberman, U. A., Delmas, P. D., Malice, M.-P., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807303390502 · Cited by 1,258
Effect of testosterone and estradiol in a man with aromatase deficiency
Carani, C., Qin, K., Simoni, M., Faustini-Fustini, M., Serpente, S., Boyd, J., Korach, K. S., & Simpson, E. R. (1997) · New England Journal of Medicine · doi:10.1056/nejm199707103370204 · Cited by 1,151
Effects of Tamoxifen on Bone Mineral Density in Postmenopausal Women with Breast Cancer
Love, R. R., Mazess, R. B., Barden, H. S., Epstein, S., Newcomb, P. A., Jordan, V. C., Carbone, P. P., & DeMets, D. L. (1992) · New England Journal of Medicine · doi:10.1056/nejm199203263261302 · Cited by 1,129
Calcium Supplementation and Increases in Bone Mineral Density in Children
Johnston, C. C., Miller, J. Z., Slemenda, C. W., Reister, T. K., Hui, S., Christian, J. C., & Peacock, M. (1992) · New England Journal of Medicine · doi:10.1056/nejm199207093270204 · Cited by 1,069
Bisphosphonates: Mechanisms of Action
Fleisch, H. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.1.0325 · Cited by 1,019
Cyclic Administration of Pamidronate in Children with Severe Osteogenesis Imperfecta
Glorieux, F. H., Bishop, N. J., Plotkin, H., Chabot, G., Lanoue, G., & Travers, R. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810013391402 · Cited by 1,015
Intermittent Cyclical Etidronate Treatment of Postmenopausal Osteoporosis
Watts, N. B., Harris, S. T., Genant, H. K., Wasnich, R. D., Miller, P. D., Jackson, R. D., Licata, A. A., Ross, P., Woodson, G. C., Yanover, M. J., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199007123230201 · Cited by 949
Noninvasive assessment of bone mineral and structure: State of the art
Genant, H. K., Engelke, K., Fuerst, T., Glüer, C.-C., Grampp, S., Harris, S. T., Jergas, M., Lang, T., Lu, Y., Majumdar, S., et al. (1996) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650110602 · Cited by 941
Storm, T., Thamsborg, G., Steiniche, T., Genant, H. K., & Sorensen, O. H. (1990) · New England Journal of Medicine · doi:10.1056/nejm199005033221803 · Cited by 935
Long-term fracture prediction by bone mineral assessed at different skeletal sites
Dr. Melton, L. J., Atkinson, E. J., O'Fallon, W. M., Wahner, H. W., & Riggs, B. L. (1993) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650081010 · Cited by 862
Ohlsson, C., Bengtsson, B.-A., Isaksson, O. G. P., Andreassen, T. T., & Slootweg, M. C. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.1.0324 · Cited by 855
Reduction in New Metastases in Breast Cancer with Adjuvant Clodronate Treatment
Diel, I. J., Solomayer, E.-F., Costa, S. D., Gollan, C., Goerner, R., Wallwiener, D., Kaufmann, M., & Bastert, G. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808063390601 · Cited by 809
Self-citationEsophagitis Associated with the Use of Alendronate
de Groen, P. C., Lubbe, D. F., Hirsch, L. J., Daifotis, A., Stephenson, W., Freedholm, D., Pryor-Tillotson, S., Seleznick, M. J., Pinkas, H., & Wang, K. K. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351403 · Cited by 764
TURNER, R. T., RIGGS, B. L., & SPELSBERG, T. C. (1994) · Endocrine Reviews · doi:10.1210/edrv-15-3-275 · Cited by 754
The Prevention and Treatment of Osteoporosis
Wood, A. J. J., Riggs, B. L., & Melton, L. J. (1992) · New England Journal of Medicine · doi:10.1056/nejm199208273270908 · Cited by 754
The crippling consequences of fractures and their impact on quality of life
Cooper, C. (1997) · The American Journal of Medicine · doi:10.1016/s0002-9343(97)90022-x · Cited by 699
Intermittent Etidronate Therapy to Prevent Corticosteroid-Induced Osteoporosis
Adachi, J. D., Bensen, W. G., Brown, J., Hanley, D., Hodsman, A., Josse, R., Kendler, D. L., Lentle, B., Olszynski, W., Ste.-Marie, L.-G., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199708073370603 · Cited by 685
Endogenous Hormones and the Risk of Hip and Vertebral Fractures among Older Women
Cummings, S. R., Browner, W. S., Bauer, D., Stone, K., Ensrud, K., Jamal, S., & Ettinger, B. (1998) · New England Journal of Medicine · doi:10.1056/nejm199809103391104 · Cited by 660
Powles, T. J., Hickish, T., Kanis, J. A., Tidy, A., & Ashley, S. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.1.78 · Cited by 646
Hypothalamic-pituitary dysfunction after radiation for brain tumors
Constine, L. S., Woolf, P. D., Cann, D., Mick, G., McCormick, K., Raubertas, R. F., & Rubin, P. (1993) · New England Journal of Medicine · doi:10.1056/nejm199301143280203 · Cited by 619
Relative Contributions of Aging and Estrogen Deficiency to Postmenopausal Bone Loss
Richelson, L. S., Wahner, H. W., Melton, L. J., & Riggs, B. L. (1984) · New England Journal of Medicine · doi:10.1056/nejm198411153112002 · Cited by 540
Chavassieux, P. M., Arlot, M. E., Reda, C., Wei, L., Yates, A. J., & Meunier, P. J. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119668 · Cited by 523
Vitamin D and bone health in the elderly
Parfitt, A. M., Gallagher, J. C., Heaney, R. P., Johnston, C. C., Neer, R., & Whedon, G. D. (1982) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/36.5.1014 · Cited by 511
Prevention of Bone Loss with Alendronate in Postmenopausal Women under 60 Years of Age
Hosking, D., Chilvers, C. E. D., Christiansen, C., Ravn, P., Wasnich, R., Ross, P., McClung, M., Balske, A., Thompson, D., Daley, M., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199802193380801 · Cited by 488
Canalis, E. (1996) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.81.10.3441 · Cited by 463
Bellido, T., Jilka, R. L., Boyce, B. F., Girasole, G., Broxmeyer, H., Dalrymple, S. A., Murray, R., & Manolagas, S. C. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117995 · Cited by 430
Reid, I. R., Ames, R. W., Evans, M. C., Gamble, G. D., & Sharpe, S. J. (1995) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)80310-6 · Cited by 429
Overgaard, K., Hansen, M. A., Jensen, S. B., & Christiansen, C. (1992) · BMJ · doi:10.1136/bmj.305.6853.556 · Cited by 426
Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice.
Sasaki, A., Boyce, B. F., Story, B. M., Wright, K. R., Chapman, M., Boyce, R. W., Mundy, G. R., & Yoneda, T. (1995) · PubMed · Cited by 417
Decreased spinal mineral content in amenorrheic women
Cann, C. E. (1984) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1984.03340290040017 · Cited by 409
Cauley, J. A., Lucas, F. L., Kuller, L. H., Stone, K., Browner, W., Cummings, S. R., & for the Study of Osteoporotic Fractures Research Group (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-4_part_1-199902160-00004 · Cited by 409
Faber, J., & Galløe, A. M. (1994) · European Journal of Endocrinology · doi:10.1530/eje.0.1300350 · Cited by 377
Adverse Effects of Bisphosphonates: A Comparative Review
Adami, S., & Zamberlan, N. (1996) · Drug Safety · doi:10.2165/00002018-199614030-00003 · Cited by 377
ERNST, M., HEATH, J. K., & RODAN, G. A. (1989) · Endocrinology · doi:10.1210/endo-125-2-825 · Cited by 364
The acute-phase response after bisphosphonate administration
Adami, S., Bhalla, A. K., Dorizzi, R., Montesanti, F., Rosini, S., Salvagno, G., & Lo Cascio, V. (1987) · Calcified Tissue International · doi:10.1007/bf02556671 · Cited by 357
Harris, S. T., Watts, N. B., Jackson, R. D., Genant, H. K., Wasnich, R. D., Ross, P., Miller, P. D., Licata, A. A., & Chesnut, C. H. (1993) · The American Journal of Medicine · doi:10.1016/0002-9343(93)90350-x · Cited by 354
ORWOLL, E. S., & KLEIN, R. F. (1995) · Endocrine Reviews · doi:10.1210/edrv-16-1-87 · Cited by 335
Mechanism and inhibition of cytochrome P-450 aromatase
Cole, P. A., & Robinson, C. H. (1990) · Journal of Medicinal Chemistry · doi:10.1021/jm00173a001 · Cited by 319
MAILLEFERT, J. F., SIBILIA, J., MICHEL, F., SAUSSINE, C., JAVIER, R. M., & TAVERNIER, C. (1999) · Journal of Urology · doi:10.1016/s0022-5347(01)61639-2 · Cited by 308
Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro.
van der Pluijm, G., Vloedgraven, H., van Beek, E., van der Wee-Pals, L., Löwik, C., & Papapoulos, S. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118841 · Cited by 305
Bone Mass and the Risk of Breast Cancer among Postmenopausal Women
Zhang, Y., Kiel, D. P., Kreger, B. E., Cupples, L. A., Ellison, R. C., Dorgan, J. F., Schatzkin, A., Levy, D., & Felson, D. T. (1997) · New England Journal of Medicine · doi:10.1056/nejm199702273360903 · Cited by 290
Prevention of Nonvertebral Fractures by Alendronate: A Meta-analysis
Karpf, D. B. (1997) · JAMA · doi:10.1001/jama.1997.03540380073035 · Cited by 281
Glucocorticoid osteoporosis--mechanisms and management
Reid, I. (1997) · European Journal of Endocrinology · doi:10.1530/eje.0.1370209 · Cited by 278
Delmas, P. D., Balena, R., Confravreux, E., Hardouin, C., Hardy, P., & Bremond, A. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.3.955 · Cited by 278
Ross, D. S., Neer, R. M., Chester Ridgway, E., & Daniels, G. H. (1987) · The American Journal of Medicine · doi:10.1016/0002-9343(87)90219-1 · Cited by 278
Brumsen, C., T. Hamdy, N. A., & Papapoulos, S. E. (1997) · Medicine · doi:10.1097/00005792-199707000-00005 · Cited by 272
A prospective study on socioeconomic aspects of fracture of the proximal femur
Schürch, M.-A., Rizzoli, R., Mermillod, B., Vasey, H., Michel, J. P., & Bonjour, J.-P. (1996) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650111215 · Cited by 266
Saarto, T., Blomqvist, C., Välimäki, M., Mäkelä, P., Sarna, S., & Elomaa, I. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.4.1341 · Cited by 265
OURSLER, M. J., CORTESE, C., KEETING, P., ANDERSON, M. A., BONDE, S. K., RIGGS, B. L., & SPELSBERG, T. C. (1991) · Endocrinology · doi:10.1210/endo-129-6-3313 · Cited by 265
Friedlaender, G. E., Tross, R. B., Doganis, A. C., Kirkwood, J. M., & Baron, R. (1984) · Journal of Bone and Joint Surgery · doi:10.2106/00004623-198466040-00016 · Cited by 265
Townsend, M. F., Sanders, W. H., Northway, R. O., & Graham, S. D. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19970201)79:3<545::aid-cncr17>3.0.co;2-3 · Cited by 260
Oestrogen Replacement Therapy for Prevention of Osteoporosis after Oophorectomy
Aitken, J. M., Hart, D. M., & Lindsay, R. (1973) · BMJ · doi:10.1136/bmj.3.5879.515 · Cited by 259
Cytokines, bone remodeling, and estrogen deficiency: a 1998 update
JILKA, R. (1998) · Bone · doi:10.1016/s8756-3282(98)00077-5 · Cited by 255
Long-term L-Thyroxine Therapy Is Associated With Decreased Hip Bone Density in Premenopausal Women
Paul, T. L. (1988) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1988.03720210027023 · Cited by 253
The Actions and Interactions of Sex Steroids and Growth Factors/Cytokines on the Skeleton
Spelsberg, T. C. (1999) · Molecular Endocrinology · doi:10.1210/me.13.6.819 · Cited by 251
Cauley, J. A. (1996) · JAMA · doi:10.1001/jama.276.17.1404 · Cited by 248
Diamond, T., Campbell, J., Bryant, C., & Lynch, W. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19981015)83:8<1561::aid-cncr11>3.0.co;2-z · Cited by 246
Halton, J. M., Dr. Atkinson, S. A., Fraher, L., Webber, C., Gill, G. J., Dawson, S., & Barr, R. D. (1996) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650111122 · Cited by 245
Patient-specific decisions about hormone replacement therapy in postmenopausal women
Col, N. F. (1997) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1997.03540380054031 · Cited by 229
The effects of Hodgkin's disease and combination chemotherapy on gonadal function in the adult male
Whitehead, E., Shalet, S. M., Blackledge, G. R. P., Todd, I. D. H., Crowther, D., & Beardwell, C. G. (1982) · Cancer · Cited by 225
Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis
Tucci, J. R., Tonino, R. P., Emkey, R. D., Peverly, C. A., Kher, U., & Santora, A. C. (1996) · The American Journal of Medicine · doi:10.1016/s0002-9343(96)00282-3 · Cited by 220
Gallagher, J. C., & Goldgar, D. (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-113-9-649 · Cited by 217
DIAMOND, T., NERY, L., & HALES, I. (1991) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-72-6-1184 · Cited by 216
Long-term thyroxine treatment and bone mineral density
FRANKLYN, J. (1992) · The Lancet · doi:10.1016/0140-6736(92)92423-d · Cited by 209
Gonadal function after bone marrow transplantation for acute leukemia during childhood
Sarafoglou, K., Boulad, F., Gillio, A., & Sklar, C. (1997) · The Journal of Pediatrics · doi:10.1016/s0022-3476(97)70345-7 · Cited by 197
Gonadal and Adrenal Androgens Are Potent Regulators of Human Bone Cell Metabolism In Vitro
Kasperk, C. H., Wakley, G. K., Hierl, T., & Ziegler, R. (1997) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1997.12.3.464 · Cited by 196
FOCAL OSTEOMALACIA DUE TO LOW-DOSE DIPHOSPHONATE THERAPY IN PAGET'S DISEASE
Boyce, B. F., Fogelman, I., Ralston, S., Smith, L., Johnston, E., & Boyle, I. T. (1984) · The Lancet · doi:10.1016/s0140-6736(84)92272-4 · Cited by 196
Leidig-Bruckner, G., Minne, H. W., Schlaich, C., Wagner, G., Scheidt-Nave, C., Bruckner, T., Gebest, H. J., & Ziegler, R. (1997) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1997.12.4.663 · Cited by 194
The Effect of a Gonadotropin-Releasing Hormone Agonist Analog (Nafarelin) on Bone Metabolism
JOHANSEN, J. S., RIIS, B. J., HASSAGER, C., MOEN, M., JACOBSON, J., & CHRISTIANSEN, C. (1988) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-67-4-701 · Cited by 189
Dose-Response Relationships for Alendronate Treatment in Osteoporotic Elderly Women1
Bone, H. G., Downs, R. W., Tucci, J. R., Harris, S. T., Weinstein, R. S., Licata, A. A., McClung, M. R., Kimmel, D. B., Gertz, B. J., Hale, E., et al. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.1.3682 · Cited by 189
Three Monthly Intravenous Injections of Ibandronate in the Treatment of Postmenopausal Osteoporosis
Thiébaud, D., Burckhardt, P., Kriegbaum, H., Huss, H., Mulder, H., Juttmann, J. R., & Schöter, K. H. (1997) · The American Journal of Medicine · doi:10.1016/s0002-9343(97)00249-0 · Cited by 186
Bone loss after liver transplantation
McDonald, J. A., Dunstan, C. R., Dilworth, P., Sherbon, K., Sheil, R. A. G., Evans, R. A., & McCaughan, G. W. (1991) · Hepatology · doi:10.1002/hep.1840140407 · Cited by 184
Bone mineral density after adjuvant chemotherapy for premenopausal breast cancer
Bruning, P., Pit, M., de Jong-Bakker, M., van den Ende, A., Hart, A., & van Enk, A. (1990) · British Journal of Cancer · doi:10.1038/bjc.1990.58 · Cited by 180
PREVENTION OF POSTMENOPAUSAL BONE LOSS BY TILUDRONATE
REGINSTER, J. (1989) · The Lancet · doi:10.1016/s0140-6736(89)92927-9 · Cited by 178
Hormonal Predictors of Bone Loss in Elderly Women: A Prospective Study
Stone, K., Bauer, D. C., Black, D. M., Sklarin, P., Ensrud, K. E., Cummings, S. R., & FOR THE STUDY OF OSTEOPOROTIC FRACTURES RESEARCH GROUP (1998) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1998.13.7.1167 · Cited by 176
Wood, A. J. J., & Toft, A. D. (1994) · New England Journal of Medicine · doi:10.1056/nejm199407213310307 · Cited by 172
Mechanisms of Bone Loss Following Allogeneic and Autologous Hemopoietic Stem Cell Transplantation
Ebeling, P. R., Thomas, D. M., Erbas, B., Hopper, J. L., Szer, J., & Grigg, A. P. (1999) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1999.14.3.342 · Cited by 171
Marcocci, C. (1994) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.78.4.818 · Cited by 170
Testicular Function After Cytotoxic Chemotherapy: Evidence of Leydig Cell Insufficiency
Howell, S. J., Radford, J. A., Ryder, W. D. J., & Shalet, S. M. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.5.1493 · Cited by 162
Effect of Hyperthyroidism and Its Treatment on Bone Mineral Content
Toh, S. H. (1985) · Archives of Internal Medicine · doi:10.1001/archinte.145.5.883 · Cited by 160
Storm, T., Steiniche, T., Thamsborg, G., & Melsen, F. (1993) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650080211 · Cited by 160
Clinical Effects of Raloxifene Hydrochloride in Women
Khovidhunkit, W., & Shoback, D. M. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-5-199903020-00015 · Cited by 159
OSTEOPOROSIS AND FRACTURES FOLLOWING THYROTOXICOSIS
Fraser, S., Smith, D. A., Anderson, J. B., & Wilson, G. M. (1971) · The Lancet · doi:10.1016/s0140-6736(71)91383-3 · Cited by 159
Faber, Jensen, Petersen, Nygaard, Hegedüs, & Siersbæk‐Nielsen (1998) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1998.00427.x · Cited by 156
Allain, T., & McGregor, A. M. (1993) · Journal of Endocrinology · doi:10.1677/joe.0.1390009 · Cited by 156
INTERMITTENT CYCLICAL ETIDRONATE IN THE PREVENTION OF CORTICOSTEROID-INDUCED BONE LOSS
Mulder, H., & Struys, A. (1994) · Lara D. Veeken · doi:10.1093/rheumatology/33.4.348 · Cited by 155
Cummings, S. R., & Black, D. M. (1995) · The American Journal of Medicine · doi:10.1016/s0002-9343(05)80041-5 · Cited by 155
Androgen effects on bone metabolism: recent progress and controversies
Hofbauer, L. C., & Khosla, S. (1999) · European Journal of Endocrinology · doi:10.1530/eje.0.1400271 · Cited by 154
Cyclical Etidronate in the Treatment of Postmenopausal Osteoporosis
Miller, P. D., Watts, N. B., Licata, A. A., Harris, S. T., Genant, H. K., Wasnich, R. D., Ross, P. D., Jackson, R. D., Hoseyni, M. S., Schoenfeld, S., et al. (1997) · The American Journal of Medicine · doi:10.1016/s0002-9343(97)00278-7 · Cited by 153
Prevalence of Fractures in Postmenopausal Women with Thyroid Disease
Solomon, B. L., Wartofsky, L., & Burman, K. D. (1993) · Thyroid · doi:10.1089/thy.1993.3.17 · Cited by 148
Valkema, R., Vismans, F. J. F. E., Papapoulos, S. E., Pauwels, E. K. J., & Bijvoet, O. L. M. (1989) · Bone and Mineral · doi:10.1016/0169-6009(89)90095-0 · Cited by 145
The effect of the antiestrogen tamoxifen on bone mineral density in normal late postmenopausal women
Grey, A. B., Stapleton, J. P., Evans, M. C., Tatnell, M. A., Ames, R. W., & Reid, I. R. (1995) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)80251-4 · Cited by 145
Skeletal integrity in premenopausal and postmenopausal women receiving long-term L-thyroxine therapy
Greenspan, S. L., Greenspan, F. S., Resnick, N. M., Block, J. E., Friedlander, A. L., & Genant, H. K. (1991) · The American Journal of Medicine · doi:10.1016/0002-9343(91)90066-7 · Cited by 143
Continuous therapy with pamidronate, a potent bisphosphonate, in postmenopausal osteoporosis
Reid, I. R., Wattie, D. J., Evans, M. C., Gamble, G. D., Stapleton, J. P., & Cornish, J. (1994) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.79.6.7989461 · Cited by 140
Mellström, D., Johansson, C., Johnell, O., Lindstedt, G., Lundberg, P. A., Obrant, K. J., Schöön, I.-M., Toss, G., & Ytterberg, B.-O. (1993) · Calcified Tissue International · doi:10.1007/bf03549778 · Cited by 137
Struys, A., Snelder, A. A., & Mulder, H. (1995) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)80154-5 · Cited by 135
COUNTERPOINT: Estrogen Effects on Calcitropic Hormones and Calcium Homeostasis
Prince, R. L. (1994) · Endocrine Reviews · doi:10.1210/edrv-15-3-301 · Cited by 134
Brennan, B. M. D., Rahim, A., Adams, J. E., Eden, O. B., & Shalet, S. M. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690296 · Cited by 132
Gordon, C. M., Grace, E., Emans, S. J., Goodman, E., CRAWFORD, M. H., & LeBoff, M. S. (1999) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1999.14.1.136 · Cited by 130
Molecular Mechanism of Action of Fluoride on Bone Cells
Lau, K. ‐. W., & Baylink, D. J. (1998) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1998.13.11.1660 · Cited by 129
Bisballe, S., Eriksen, E. F., Melsen, F., Mosekilde, L., Sørensen, O. H., & Hessov, I. (1991) · Gut · doi:10.1136/gut.32.11.1303 · Cited by 128
Selective Estrogen Receptor Modulators: A Look Ahead
Mitlak, B., & Cohen, F. J. (1999) · Drugs · doi:10.2165/00003495-199957050-00001 · Cited by 128
Marttunen, M. B., Hietanen, P. S., Tiitinen, A. E., & Ylikorkala, O. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.4.4688 · Cited by 127
Ward, R. L., Morgan, G., Dalley, D. N., et al. (1993) · Bone and Mineral · doi:10.1016/s0169-6009(08)80220-6 · Cited by 125
Nephrotoxicity after ifosfamide.
Skinner, R., Pearson, A. D. J., Price, L., Coulthard, M. G., & Craft, A. W. (1990) · Archives of Disease in Childhood · doi:10.1136/adc.65.7.732 · Cited by 125
Prevention of Corticosteroid-Induced Osteoporosis with Alendronate in Sarcoid Patients
Gonnelli, S., Rottoli, P., Cepollaro, C., Pondrelli, C. R., Cappiello, V., Vagliasindi, M., & Gennari, C. (1997) · Calcified Tissue International · doi:10.1007/s002239900352 · Cited by 124
Perspectives: Posttransplantation bone disease
Katz, I. A., & Epstein, S. (1992) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650070202 · Cited by 119
Ovarian function following the treatment of childhood acute lymphoblastic leukaemia
Wallace, W. H., Shalet, S. M., Tetlow, L. J., & Morris-Jones, P. (1993) · Medical and Pediatric Oncology · doi:10.1002/mpo.2950210505 · Cited by 119
Thyrotoxic Bone Disease in Women: A Potentially Reversible Disorder
DIAMOND, T. H., Vine, J., Smart, R., & Butler, P. (1994) · Annals of Internal Medicine · doi:10.7326/0003-4819-120-1-199401010-00002 · Cited by 119
Hamilton, A. L., & Piccart, M. J. (1999) · Annals of Oncology · doi:10.1023/a:1008368300827 · Cited by 118
Wolfhagen, F. H. J., van Buuren, H. R., den Ouden, J. W., Hop, W. C. J., van Leeuwen, J. P. T. M., Schalm, S. W., & Pols, H. A. P. (1997) · Journal of Hepatology · doi:10.1016/s0168-8278(97)80048-7 · Cited by 116
Dose-Response Relationships for Alendronate Treatment in Osteoporotic Elderly Women
Bone, H. G. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.82.1.265 · Cited by 114
Thiébaud, D., Burckhardt, P., Melchior, J., Eckert, P., Jacquet, A. F., Schnyder, P., & Gobelet, C. (1994) · Osteoporosis International · doi:10.1007/bf01623227 · Cited by 112
Review of the evidence for an association between infant feeding and childhood cancer
Davis, M. K. (1998) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(1998)78:11+<35::aid-ijc11>3.0.co;2-i · Cited by 111
Miller, K. K., & Klibanski, A. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.6.5688 · Cited by 110
Rosen, C. J., & Adler, R. A. (1992) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.75.6.1464660 · Cited by 110
Reeves, H. L., Francis, R. M., Manas, D., Hudson, M., & Day, C. P. (1998) · Liver Transplantation and Surgery · doi:10.1002/lt.500040508 · Cited by 108
PREVENTION OF BONE LOSS IN CARDIAC TRANSPLANT RECIPIENTS
Cleemput, J. V., Daenen, W., Geusens, P., Dequeker, J., de Werf, F. V., & Vanhaecke, J. (1996) · Transplantation · doi:10.1097/00007890-199605270-00015 · Cited by 107
AzaThioprine alone is bone sparing and does not alter cyclosporin A-induced osteopenia in the rat
Bryer, H. P., Isserow, J. A., Armstrong, E. C., Mann, G. N., Rucinski, B., Buchinsky, F. J., Romero, D. F., & Epstein, S. (1995) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650100119 · Cited by 105
The treatment of osteoporosis with disodium ethane-1, 1-diphosphonate.
Jowsey, J., Riggs, B. L., Pj, K., Dl, H., & Bordier, P. (1971) · PubMed · Cited by 104
Raymond, J. P., Izembart, M., MARLIAC, V., Dagousset, F., Merceron, R. E., Vulpillat, M., & VALLUÉ, G. (1989) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-69-1-186 · Cited by 104
Bone loss after cardiac transplantation: Effects of calcium, calcidiol and monofluorophosphate
Meys, E., Terreaux, F., Beaume-Six, T., Dureau, G., & Meunier, P. J. (1993) · Osteoporosis International · doi:10.1007/bf01637318 · Cited by 99
Effects of one-year cyclical treatment with clodronate on postmenopausal bone loss
Giannini, S., D’Angelo, A., Malvasi, L., et al. (1993) · Bone · doi:10.1016/8756-3282(93)90240-b · Cited by 95
NUTTALL, M. E., Bradbeer, J. N., Stroup, G. B., Nadeau, D. P., Hoffman, S. J., Zhao, H. Q., Rehm, S., & Gowen, M. (1998) · Endocrinology · doi:10.1210/endo.139.12.6343 · Cited by 94
Radiation and Pituitary Dysfunction
Shalet, S. M. (1993) · New England Journal of Medicine · doi:10.1056/nejm199301143280211 · Cited by 94
Update on endocrine therapy for breast cancer.
Buzdar, A. U., & Hortobágyi, G. N. (1998) · PubMed · Cited by 91
Brodie, A., Lü, Q., & Long, B. J. (1999) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(99)00051-5 · Cited by 90
New endocrine therapies for breast cancer
Howell, A., Downey, S. E., & Anderson, E. (1996) · European Journal of Cancer · doi:10.1016/0959-8049(96)00032-9 · Cited by 90
Clinical Pharmacokinetics of the Antiandrogens and Their Efficacy in Prostate Cancer
Mahler, C., Verhelst, J. A., & Denis, L. (1998) · Clinical Pharmacokinetics · doi:10.2165/00003088-199834050-00005 · Cited by 89
Intermittent cyclic therapy with etidronate in the prevention of corticosteroid induced bone loss.
Adachi, J. D., Cranney, A., Ch, G., Wg, B., Bianchi, F. A., Cividino, A. A., Gl, C., Kamińska, E., Sebaldt, R. J., & Παπαϊωάννου, Α. (1994) · PubMed · Cited by 89
Endocrine complications after radiotherapy for tumors of the head and neck.
Samaan, N. A., Schultz, P. N., Yang, K.-P., Vassilopoulou‐Sellin, R., Maor, M. H., Cangır, A., & Goepfert, H. (1987) · PubMed · Cited by 87
Plowchalk, D. R., & Mattison, D. R. (1992) · Reproductive Toxicology · doi:10.1016/0890-6238(92)90004-d · Cited by 85
Houben, K. W., & McCall, J. L. (1999) · Liver Transplantation and Surgery · doi:10.1002/lt.500050201 · Cited by 84
Endocrine, Paracrine and Autocrine Regulation of Testicular Steroidogenesis
Huhtaniemi, I., & Toppari, J. (1995) · Advances in Experimental Medicine and Biology · doi:10.1007/978-1-4899-0952-7_3 · Cited by 82
Calcitonin for prevention and treatment of osteoporosis
Reginster, J. (1993) · The American Journal of Medicine · doi:10.1016/0002-9343(93)90382-y · Cited by 81
Bone mass measurement: Prediction of risk
Wasnich, R. D. (1993) · The American Journal of Medicine · doi:10.1016/0002-9343(93)90374-x · Cited by 81
Chemotherapy-induced premature ovarian failure: Mechanisms and prevention
Ataya, K. M., & Moghissi, K. S. (1989) · Steroids · doi:10.1016/0039-128x(89)90084-6 · Cited by 81
Hormone replacement therapy for prevention and treatment of osteoporosis
Lindsay, R. (1993) · The American Journal of Medicine · doi:10.1016/0002-9343(93)90380-8 · Cited by 81
Gallacher, S., Fenner, J. A. K., Anderson, K., Bryden, F., Banham, S. W., Logue, F. C., Cowan, R. A., & Boyle, I. T. (1992) · Thorax · doi:10.1136/thx.47.11.932 · Cited by 80
Use of cyclical etidronate and prevention of non-vertebral fractures
van Staa, T. P., Abenhaim, L., & Cooper, C. C. (1998) · Rheumatology · doi:10.1093/rheumatology/37.1.87 · Cited by 79
Graham, D. Y., Malaty, H. M., & Goodgame, R. (1997) · PubMed · Cited by 77
Passeri, M., Baroni, M. C., Pedrazzoni, M., Pioli, G., Barbagallo, M., Costi, D., Biondi, M., Girasole, G., Arlunno, B., & Palummeri, E. (1991) · Bone and Mineral · doi:10.1016/0169-6009(91)90129-n · Cited by 75
SEVERE OSTEOPOROSIS DUE TO SYSTEMIC MAST CELL DISEASE: SUCCESSFUL TREATMENT WITH INTERFERON ALPHA-2B
Lehmann, T., Beyeler, C., Lämmle, B., Hunziker, T., Vock, P., OLAH, A. J., Dahinden, C. A., & GERBER, N. J. (1996) · Lara D. Veeken · doi:10.1093/rheumatology/35.9.898 · Cited by 74
Reduced bone mineral density in men following chemotherapy for Hodgkin's disease
Holmes, S., Whitehouse, R., Clark, S., Crowther, D., Adams, J. E., & Shalet, S. M. (1994) · British Journal of Cancer · doi:10.1038/bjc.1994.308 · Cited by 73
Ziegler, R., Scheidt‐Nave, C., & Leidig‐Bruckner, G. (1996) · Bone · doi:10.1016/8756-3282(95)00498-x · Cited by 72
Williams, G. R., Robson, H., & Shalet, S. M. (1998) · Journal of Endocrinology · doi:10.1677/joe.0.1570391 · Cited by 69
Therapy with parenteral pamidronate prevents thyroid hormone-induced bone turnover in humans
Rosen, H. N., Moses, A. C., Gundberg, C. M., Kung, V. T., Seyedin, S. M., Chen, T. C., Holick, M. F., & Greenspan, S. L. (1993) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.77.3.8370687 · Cited by 69
Maines, M. D., Sluss, P. M., & İşcan, M. (1990) · Endocrinology · doi:10.1210/endo-126-5-2398 · Cited by 69
Reduction of Bone Mass in Women after Bone Marrow Transplantation
Castañeda, S., Carmona, L., Carvajal, I., Arranz, R., Díaz, A., & García-Vadillo, A. (1997) · Calcified Tissue International · doi:10.1007/s002239900240 · Cited by 67
Effects of methotrexate on human osteoblasts in vitro: Modulation by 1,25-dihydroxyvitamin D3
Scheven, B. A. A., van der Veen, M. J., Damen, C. A., et al. (1995) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650100608 · Cited by 67
Bisphosphonates in the Treatment of Malignant Bone Disease
Berenson, J. R., & Lipton, A. (1999) · Annual Review of Medicine · doi:10.1146/annurev.med.50.1.237 · Cited by 65
Skeletal Integrity in Men Chronically Treated with Suppressive Doses of L-Thyroxine
Marcocci, C., Golia, F., Vignali, E., & Pinchera, A. (1997) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1997.12.1.72 · Cited by 64
Pioli, G., Pedrazzoni, M., Palummeri, E., Sianesi, M., Frate, R. D., Vescovi, P. P., Prisco, M., Ulietti, V., Costi, D., & Passeri, M. (1992) · European Journal of Endocrinology · doi:10.1530/acta.0.1260238 · Cited by 63
FROMM, G. A., Vega, E., Plantalech, L., Galich, A. M., & Mautalén, C. (1991) · Osteoporosis International · doi:10.1007/bf01625440 · Cited by 62
Endocrinological late effects after chemotherapy for testicular cancer
Berger, C. C., Bokemeyer, C., Schuppert, F., & Schmoll, H. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.213 · Cited by 60
Jódar, E., Begoña López, M., García, L., Rigopoulou, D., Martínez, G., & Hawkins, F. (1998) · Osteoporosis International · doi:10.1007/s001980050069 · Cited by 59
Interferon and Malignant Disease - How Does it Work and Why Doesn't it Always?
Grandér, D., & Einhorn, S. (1998) · Acta Oncologica · doi:10.1080/028418698430548 · Cited by 58
REDUCED BONE MINERAL DENSITY IN MEN AND WOMEN WITH ALLOGENEIC BONE MARROW TRANSPLANTATION
&NA; (1990) · Transplantation · doi:10.1097/00007890-199011000-00028 · Cited by 57
A Risk-Benefit Assessment of Tamoxifen Therapy
Catherino, W. H., & Jordan, V. C. (1993) · Drug Safety · doi:10.2165/00002018-199308050-00005 · Cited by 55
Martel, C., Sourla, A., Pelletier, G., Labrie, C., Fournier, M., Picard, S., Li, S., Stojanovic, M. M., & Labrie, F. (1998) · Journal of Endocrinology · doi:10.1677/joe.0.1570433 · Cited by 55
Imawari, M., Kozawa, K., Akanuma, Y., 小泉, 澄., Itakura, H., & Kosáka, K. (1980) · Gastroenterology · doi:10.1016/0016-5085(80)90137-7 · Cited by 55
Evidence that Tamoxifen Preserves Bone Density in Late Postmenopausal Women with Breast Cancer
Resch, A., Biber, E., Seifert, M., & Resch, H. (1998) · Acta Oncologica · doi:10.1080/028418698430007 · Cited by 53
Duncan, W. E., CHANG, A., Solomon, B. L., & Wartofsky, L. (1994) · Thyroid · doi:10.1089/thy.1994.4.183 · Cited by 50
Chieng, P., Huang, T., Chang, C.-C., Chong, P.-Y., Tien, R. D., & Su, C. (1991) · PubMed Central · Cited by 46
Bone mineralization in women following successful treatment of Hodgkin's disease
Redman, J. R., Bajorunas, D. R., Wong, G. Y., McDermott, K., Gnecco, C., Schneider, R. J., Lacher, M. J., & Lane, J. M. (1988) · The American Journal of Medicine · doi:10.1016/0002-9343(88)90504-9 · Cited by 46
Upper Gastrointestinal Adverse Events and Cyclical Etidronate
van Staa, T. P., Abenhaim, L., & Cooper, C. C. (1997) · The American Journal of Medicine · doi:10.1016/s0002-9343(97)00242-8 · Cited by 45
Miller, K. K. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.6.1775 · Cited by 44
The effects of the aminobisphosphonate alendronate on thyroid hormone-induced osteopenia in rats
Yamamoto, M., Markatos, A., Seedor, J. G., Masarachia, P. J., Gentile, M., Rodan, G. A., & Balena, R. (1993) · Calcified Tissue International · doi:10.1007/bf01320914 · Cited by 42
Montessori, M. L. M., Scheele, W. H., Netelenbos, J. C., Kerkhoff, J. F., & Bakker, K. (1997) · Osteoporosis International · doi:10.1007/bf01623461 · Cited by 38
Bisphosphonates in multiple myeloma
Berenson, J. R. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19971015)80:8+<1661::aid-cncr16>3.0.co;2-y · Cited by 35
Growth and pubertal development in survivors of childhood cancer.
Sklar, C. A. (1991) · PubMed · Cited by 33
Vertebral Compression in Childhood Leukemia
Newman, A. J. (1973) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/archpedi.1973.04160060065015 · Cited by 32
Osteoporosis occurring in two patients receiving LHRH analogs for carcinoma of the prostate
Collinson, M. P., TYRRELL, C. J., & Hutton, C. (1994) · Calcified Tissue International · doi:10.1007/bf00295959 · Cited by 31
THE PITUITARY‐LEYDIG CELL AXIS IN MEN WITH SEVERE DAMAGE TO THE GERMINAL EPITHELIUM
Tsatsoulis, A. A., Whitehead, E., JOHN, J. S., et al. (1987) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1987.tb02952.x · Cited by 31
Kauppila, Viikari, Irjala, Koskinen, & Remes (1998) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.1998.00390.x · Cited by 30
Future uses for aromatase inhibitors in breast cancer
Dowsett, M. (1997) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(97)80021-0 · Cited by 29
Blatt, J., Martini, S. L., & Penchansky, L. (1984) · The Journal of Pediatrics · doi:10.1016/s0022-3476(84)80132-8 · Cited by 29
Segawa, Y., Yamaura, M., Aota, S., Omata, T., Tuzuike, N., Itokazu, Y., Oka, H., Tamaki, H., & Nakamura, T. (1997) · Bone · doi:10.1016/s8756-3282(97)00023-9 · Cited by 27
Vertebral compression fractures at the onset of acute lymphoblastic leukemia in a child.
Oliveri, B., Mautalén, C., Fuchs, C. R., & Mc, R. (1991) · PubMed · Cited by 27
Role of oral pamidronate in preventing bone loss in postmenopausal women
Lees, B., Garland, S. W., Walton, C., Ross, D., Whitehead, M., & Stevenson, J. C. (1996) · Osteoporosis International · doi:10.1007/bf01629581 · Cited by 26
Tissue-Specific Estrogens — The Promise for the Future
Fuleihan, G. E. (1997) · New England Journal of Medicine · doi:10.1056/nejm199712043372309 · Cited by 23
Beresford, J. N., TAYLOR, G. T., & Triffitt, J. T. (1990) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1990.tb19377.x · Cited by 21
Reduction of Testosterone Synthesis after High Dose Interleukin-2 Therapy of Metastatic Cancer*
Meikle, A. W., SOUSA, J. C. C. D., Ward, J. H., Woodward, M. G., & Samlowski, W. E. (1991) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-73-5-931 · Cited by 20
Blatt, J., Lee, P. A., Suttner, J., & Finegold, D. N. (1988) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(88)90138-1 · Cited by 20
Tsuda-Futami, E., Shioi, A., Jono, S., Inaba, M., Nishizawà, Y., & Morii, H. (1998) · Bone · doi:10.1016/s8756-3282(98)00094-5 · Cited by 15
Growth hormone and the maintenance of adult bone mineral density
Inzucchi, S. E., & Robbins, R. J. (1996) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1996.8750885.x · Cited by 14
Kohler, G., Shen, V., & Peck, W. A. (1984) · Calcified Tissue International · doi:10.1007/bf02405331 · Cited by 12
Controversies in the management of advanced prostate cancer
Tyrrell, C. (1998) · British Journal of Cancer · doi:10.1038/sj.bjc.6690024 · Cited by 11
Cited by
Cancer treatment and survivorship statistics, 2012
Siegel, R., DeSantis, C., Virgo, K., Stein, K., Mariotto, A., Smith, T., Cooper, D., Gansler, T., Lerro, C., Fedewa, S., et al. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21149 · Cited by 2,928
Aapro, M., Abrahamsson, P. A., Body, J. J., Coleman, R. E., Colomer, R., Costa, L., Crinò, L., Dirix, L., Gnant, M., Gralow, J., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdm442 · Cited by 457
NCCN Task Force Report: Bone Health in Cancer Care
Gralow, J. R., Biermann, J. S., Farooki, A., Fornier, M. N., Gagel, R. F., Kumar, R., Litsas, G., McKay, R., Podoloff, D. A., Srinivas, S., et al. (2013) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2013.0215 · Cited by 412
Fracture Risk With Multiple Myeloma: A Population-Based Study
Melton, L. J., Kyle, R. A., Achenbach, S. J., Oberg, A. L., & Rajkumar, S. V. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.041131 · Cited by 332
Lønning, P. E., Geisler, J., Krag, L. E., Erikstein, B., Bremnes, Y., Hagen, A. I., Schlichting, E., Lien, E. A., Øfjord, E. S., Paolini, J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.097 · Cited by 295
Metadata
- Authors
- Pfeilschifter, J., & Diel, I. J.
- Venue
- Journal of Clinical Oncology
- Published
- 2000-04-07
- Volume
- 18
- Issue
- 7
- Pages
- 1570-1593
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1928668153
- Cited by
- 363
- References
- 202
- FWCI
- 7.99
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.